Literature DB >> 3584468

Metabolism of immunoglobulin E in patients with markedly elevated serum immunoglobulin E levels.

S C Dreskin, P K Goldsmith, W Strober, L A Zech, J I Gallin.   

Abstract

The metabolism of human IgE was studied in normals, severe atopics, and patients with the hyperimmunoglobulin E-recurrent infection (HIE; Job's) syndrome to determine whether IgE metabolism is altered in patients with marked elevation of serum IgE. Purified polyclonal 125I-IgE was administered intravenously and serial plasma and urine samples were obtained. After analysis, the metabolic data support previously published evidence that IgE (at concentrations found in normal individuals) is catabolized at a higher fractional rate than other immunoglobulins and is catabolized by both an intravascular and an extravascular pathway. In addition, the data show that the fractional catabolic rate for IgE is significantly less for the atopic patients (mean +/- SEM = 0.20 +/- 0.01) and for the HIE patients (0.15 +/- 0.02) than for the normal volunteers (0.52 +/- 0.06; P less than 0.01) and is inversely related (r = -0.851; P less than 0.001) to the serum IgE concentration. These findings have specific importance in showing that decreased fractional catabolic rate contributes substantially to elevation of IgE in atopic and HIE patients. In addition, the findings have general significance in that they lead to a unifying hypothesis of immunoglobulin catabolism.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3584468      PMCID: PMC424519          DOI: 10.1172/JCI113017

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  29 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

2.  Disappearance of intradermally administered plasma immunoglobulins and skin-sensitizing antibodies.

Authors:  P Fireman; M Boesman; D Gitlin
Journal:  J Allergy       Date:  1967-11

3.  Biologic properties of E myeloma proteins.

Authors:  M Ogawa; O R McIntyre; K Ishizaka; T Ishizaka; W D Terry; T A Waldmann
Journal:  Am J Med       Date:  1971-08       Impact factor: 4.965

4.  Immunoglobulin metabolism in ataxia telangiectasia.

Authors:  W Strober; R D Wochner; M H Barlow; D E McFarlin; T A Waldmann
Journal:  J Clin Invest       Date:  1968-08       Impact factor: 14.808

Review 5.  Metabolism of immunoglobulins.

Authors:  T A Waldmann; W Strober
Journal:  Prog Allergy       Date:  1969

6.  The disapperance rate of skin-sensitizing antibody activity after intradermal administration.

Authors:  R M Cass; B R Andersen
Journal:  J Allergy       Date:  1968-07

7.  Metabolism of human immunoglobulin D (IgD).

Authors:  G N Rogentine; D S Rowe; J Bradley; T A Waldmann; J L Fahey
Journal:  J Clin Invest       Date:  1966-09       Impact factor: 14.808

8.  The metabolism of IgE. Studies in normal individuals and in a patient with IgE myeloma.

Authors:  T A Waldmann; A Iio; M Ogawa; O R McIntyre; W Strober
Journal:  J Immunol       Date:  1976-10       Impact factor: 5.422

9.  IgE receptors on human basophils. Relationship to serum IgE concentration.

Authors:  F J Malveaux; M C Conroy; N F Adkinson; L M Lichtenstein
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

10.  The metabolism of IgE in patients with immunodeficiency states and neoplastic conditions.

Authors:  A Iio; W Strober; S Broder; S H Polmar
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

View more
  19 in total

1.  Murine B cells regulate serum IgE levels in a CD23-dependent manner.

Authors:  Laurence E Cheng; Zhi-En Wang; Richard M Locksley
Journal:  J Immunol       Date:  2010-09-24       Impact factor: 5.422

2.  Serum IgE clearance is facilitated by human FcεRI internalization.

Authors:  Alexandra M Greer; Nan Wu; Amy L Putnam; Prescott G Woodruff; Paul Wolters; Jean-Pierre Kinet; Jeoung-Sook Shin
Journal:  J Clin Invest       Date:  2014-02-24       Impact factor: 14.808

3.  Conformational IgE epitopes of peanut allergens Ara h 2 and Ara h 6.

Authors:  Xueni Chen; Surendra S Negi; Sumei Liao; Valerie Gao; Werner Braun; Stephen C Dreskin
Journal:  Clin Exp Allergy       Date:  2016-06-27       Impact factor: 5.018

4.  Genetic linkage of hyper-IgE syndrome to chromosome 4.

Authors:  B Grimbacher; A A Schäffer; S M Holland; J Davis; J I Gallin; H L Malech; T P Atkinson; B H Belohradsky; R H Buckley; F Cossu; T Español; B Z Garty; N Matamoros; L A Myers; R P Nelson; H D Ochs; E D Renner; N Wellinghausen; J M Puck
Journal:  Am J Hum Genet       Date:  1999-09       Impact factor: 11.025

Review 5.  IgE immunotherapy against cancer.

Authors:  Lai Sum Leoh; Tracy R Daniels-Wells; Manuel L Penichet
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

Review 6.  The role of FcεRI expressed in dendritic cells and monocytes.

Authors:  Jeoung-Sook Shin; Alexandra M Greer
Journal:  Cell Mol Life Sci       Date:  2015-02-26       Impact factor: 9.261

7.  Management of acquired peanut allergy following solid-organ transplant.

Authors:  Carolyn Word; Erin Klaffky; Christina Ortiz; Thamiris Palacios; Shawn Pelletier; Walter Oliveira; Barbara Greb; Lisa Workman; Thomas Platts-Mills; Julia Wisniewski
Journal:  J Allergy Clin Immunol Pract       Date:  2015-04-22

8.  Analysis of IgE turnover in non-sensitized and sensitized rats.

Authors:  K Hanashiro; Y Tokeshi; T Nakasone; M Sunagawa; M Nakamura; T Kosugi
Journal:  Mediators Inflamm       Date:  2001-08       Impact factor: 4.711

Review 9.  IgE immunotherapy: a novel concept with promise for the treatment of cancer.

Authors:  Debra H Josephs; James F Spicer; Panagiotis Karagiannis; Hannah J Gould; Sophia N Karagiannis
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

10.  Evidence for an interleukin 4-inducible immunoglobulin E uptake and transport mechanism in the intestine.

Authors:  K Ramaswamy; J Hakimi; R G Bell
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.